GlobeNewswire

COAST Autonomous Optimizes Self Driving Vehicle Safety with LeddarTech’s Cocoon LiDAR

Del

COAST Autonomous selects LeddarTech’s solid-state LiDAR technology as the most reliable solution to achieve maximum safety levels for its self-driving vehicles designed for campus and urban environments.

QUEBEC CITY, June 04, 2019 (GLOBE NEWSWIRE) -- LeddarTech ®, an industry leader in automotive and mobility LiDAR technology, is pleased to announce that COAST Autonomous has selected LeddarTech for its autonomous shuttles. COAST Autonomous, founded by veterans of the self-driving industry, chose LeddarTech’s technology because of its ability to deliver enhanced safety for COAST Autonomous’ vehicles. The robustness and reliability of LeddarTech’s solid-state technology meet today’s demanding mobility conditions and makes it the technology of choice toward preventing collisions in stop-and-go applications by eliminating dead zones left by other sensing technologies.

COAST Autonomous has developed self-driving vehicles that integrate several detection technologies, including LiDAR, RADAR, and camera. LeddarTech’s LiDAR provides full coverage with no dead zones within the entire perimeter of the vehicle, also referred to as the cocoon. This protects vulnerable road users such as pedestrians who may approach the vehicle in stop-and-go situations.  LeddarTech’s cocoon LiDAR provides a unique solution enabling safe, fully autonomous vehicles. “With the intent of providing the safest rides to our passengers, our selection of detection technologies takes into consideration the maturity of the partners we work with and their ability to consistently deliver on their promises,” stated Pierre Lefevre, Chief Technology Officer at COAST Autonomous. “With more than a decade of experience building LiDAR sensors, LeddarTech is the perfect partner for us and has consistently shown it could exceed our expectations.”

“We are honored that our cocoon LiDAR solutions were selected and trusted by COAST Autonomous to be part of its self-driving vehicles,” stated Adrian Pierce, VP of Global Sales & Business Development of LeddarTech. He went on to say, “COAST has an amazing track record with over 60 trials in 7 different countries and impressive history of transporting over 120,000 passengers. The first element of Coast’s charter is safety first, and the deployment of LeddarTech’s cocoon LiDAR supports that charter and the commitment Coast makes to their customers. ” Mr. Pierce concluded that “making mobility applications safer is at the core of our DNA. Our technology offers the right balance of performance and cost-effectiveness and is ready for deployment today.”

About COAST Autonomous

COAST Autonomous is a software and technology company focused on delivering AV solutions at appropriate speeds for urban and campus environments. COAST’s mission is to build community by connecting people with mobility solutions that put pedestrians first and give cities back to people. At the center of one of the fastest and most profound disruptions to impact the transportation and logistics industries, COAST has developed the full stack of Autonomous Vehicle (AV) software that includes mapping and localization, robotics and artificial intelligence (AI), fleet management and supervision systems. Partnering with proven manufacturers, COAST can provide a variety of vehicles equipped with its best-in-class software to offer Mobility-as-a-Service (MaaS) solutions to cities, theme parks, campuses, airports, and other urban environments. Based in Pasadena, California, COAST’s team is recognized for its experience and expertise in all aspects of implementing and operating AV fleets while prioritizing safety and the user experience. To learn how COAST Autonomous can help you power autonomous transportation in your environment, please visit www.coastautonomous.com.

Contact: Aimie Nghiem, Director of Program Development, COAST Autonomous
Tel: +1-626-838-2469 ANghiem@coastautonomous.com

About LeddarTech®

LeddarTech is an industry leader providing the most versatile and scalable automotive LiDAR development platform based on the unique LeddarEngineTM which consists of a suite of automotive-grade, functional safety certified SoCs working in tandem with proprietary LeddarSP signal processing software. The company is responsible for several innovations in cutting-edge mobility remote-sensing applications, with over 70 patented technologies (20 pending) enhancing ADAS and autonomous driving capabilities for automobiles.

LeddarTech also serves the mobility market with solid-state high-performance LiDAR module solutions for autonomous shuttles, trucks, buses, delivery vehicles and robotaxis.

Additional information about LeddarTech is accessible at www.LeddarTech.com, and on LinkedInTwitterFacebook, and YouTube.

Contact: Daniel Aitken, Vice President of Marketing and Communications, LeddarTech
Tel.: +1-418-653-9000 ext. 232 Daniel.Aitken@Leddartech.com

Leddar, LeddarTech, and LeddarTech logos are trademarks or registered trademarks of LeddarTech Inc. All other brands, product names, and marks are or may be trademarks or registered trademarks used to identify products or services of their respective owners.

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

Apellis Pharmaceuticals Presents Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at 24th European Hematology Association (EHA) Congress15.6.2019 16:00:00 CESTPressemelding

CRESTWOOD, Ky. and WALTHAM Mass., June 15, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced updated data from its Phase 2 PLAUDIT study of APL-2 in patients with autoimmune hemolytic anemia (AIHA), including cold agglutinin disease (CAD) and warm antibody autoimmune hemolytic anemia (wAIHA). Data from the PLAUDIT trial will be presented in an oral presentation today at the 24th Annual Congress of the European Hematology Association (EHA), held in Amsterdam, the Netherlands. In the ongoing PLAUDIT study, 13 patients with CAD have been enrolled to receive subcutaneous APL-2 treatment, of which 10 patients have been on APL-2 for at least 168 days. The trial has also enrolled 11 patients with wAIHA, 8 of which were Direct Antiglobulin Test (DAT) C3+ (C3+ wAIHA); 5 of the C3+ wAIHA patients

Carpenter Technology and BMT Aerospace Combine Expertise in Redesign and Production of Additively Manufactured Aerospace Component14.6.2019 15:17:00 CESTPressemelding

LE BOURGET, France, June 14, 2019 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation (NYSE:CRS) and Belgium-based BMT Aerospace today announced their cooperation in the development of an additively manufactured (AM) aerospace pinion, using Carpenter Technology’s Custom 465® Stainless. BMT Aerospace and its subsidiary BMT Additive initiated the project by partnering with Carpenter Technology to produce a redesigned pinion. The redesign project was initiated to enable the benefits of additive manufacturing using high quality, printable material that would attain the high-performance expectations for the application. “BMT Aerospace strongly believes in the disruptive potential of additive manufacturing and its possibilities in aerospace,” explained Ewald Goossens, Business Unit Manager of BMT Additive. “As a small player in the market, we strongly believe in cooperation opportunities like these, where each partner can rely and build on a project, starting from its own expertise. Our spe

Immunophotonics and Clinical Laserthermia Systems Announce Immuno-Oncology Research Collaboration and Clinical Trials for Cancer Patients with Solid Tumors14.6.2019 13:00:00 CESTPressemelding

Collaboration will Combine Immunophotonics’ Proprietary Drug, IP-001, and CLS’s TRANBERG Laser Thermal Therapy System and imILT Method ST. LOUIS and LUND, Sweden, June 14, 2019 (GLOBE NEWSWIRE) -- Immunophotonics, Inc. and Clinical Laserthermia Systems, AB (STO:CLS B) (CLS) today announced they have entered into a research collaboration agreement to support a Phase 1b/2a clinical trial for cancer patients with certain solid tumor indications. The research will utilize each company’s respective products and methodologies during treatments and is intended to support early phase clinical trials facilitated by a leading clinical organization. Eligible patients with solid tumors will be treated using the locally administered CLS Immunostimulating Interstitial Laser Thermotherapy (imILT) method, followed immediately by an intratumoral injection of Immunophotonics’ lead asset, IP-001. Under the agreement, the CLS TRANBERG Laser and single-use products will be used in eligible patients enrolle

iCAD Introduces ProFound AI™ for 2D Mammography in Europe13.6.2019 14:00:00 CESTPressemelding

Company to showcase its newest artificial intelligence software solution, ProFound AI for 2D Mammography, in addition to ProFound AI for Digital Breast Tomosynthesis at the SIFEM Medical Conference in France NASHUA, N.H. and LILLE, France, June 13, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the launch of ProFound AI™ for 2D Mammography in Europe. This software is the latest addition to iCAD’s deep-learning, artificial intelligence platform and follows the launch of ProFound AI™ for Digital Breast Tomosynthesis (DBT), which was CE Marked in March 2018 and FDA cleared in December 2018. ProFound AI for 2D Mammography and ProFound AI for DBT will both be featured in the iCAD exhibition booth (#24) at the Société Française d'Imagerie de la FEMme (SIFEM) medical conference from June 13-15, 2019 at the Grand Palais in Lille, France. “iCAD is at the forefront of the fight ag

Telix Pharmaceuticals and Eczacıbaşı-Monrol Sign Manufacturing and Distribution Agreement13.6.2019 13:54:00 CESTPressemelding

MELBOURNE, Australia and ISTANBUL, Turkey, June 13, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR) has today announced that it has concluded a master services and distribution agreement with Eczacıbaşı-Monrol. Under the terms of the agreement, Telix has appointed Eczacıbaşı-Monrol as a radiopharmaceutical production partner and distributor in Turkey/Middle East/North Africa. Eczacıbaşı-Monrol is commercially active in more than 40 countries, including important growth territories that complement Telix’s current commercial strategy for the US and Europe. The parties will initially focus on the production and distribution of TLX250-CDx (89Zr-girentuximab) for imaging of renal cell carcinoma with Positron Emission Tomography (PET), including to support the ad

Highly Accurate Long-Read Sequencing of Human Genomes Leads to Discovery of Disease-Causing Variants13.6.2019 13:30:00 CESTPressemelding

Identification of pathogenic structural variants with SMRT Sequencing improves solve rate for rare and Mendelian diseases MENLO PARK, Calif., June 13, 2019 (GLOBE NEWSWIRE) -- While DNA sequencing tools have been useful for determining the genetic cause of many diseases, there remain a large number that are left unexplained. Recently, scientists have adopted Single Molecule, Real-Time (SMRT®) Sequencing from Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, to study previously unsolved diseases. Many high-impact research publications report expanded variant detection in human genomes, leading to discovery of disease-causing variants and genes underlying rare and Mendelian disorders. In a Nature Communications publication, scientists report that most structural variants (SVs) and large indels are undetected in today’s human genetic studies, which likely accounts for some of the missing heritabi